Health Bulletin Haiti
SEE OTHER BRANDS

Your health and wellness news from Haiti

Health Bulletin Haiti: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Bulletin Haiti.

Press releases published on June 5, 2025

Attention Craft Beer Fans! Tilray Beverages Highlights Boldest Brews For Summer

Attention Craft Beer Fans! Tilray Beverages Highlights Boldest Brews For Summer

ATLANTA, June 05, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is turning up the heat this summer with a …

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at …

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people

In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South America Celebrating a decade of impact with strong progress towards the Foundation’s 2030 …

Cutest Pets on Parliament Hill 2025: Winners Unveiled at Purr-fectly Playful Pet Gala

Cutest Pets on Parliament Hill 2025: Winners Unveiled at Purr-fectly Playful Pet Gala

OTTAWA, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- It was paws-itively unforgettable at the 3rd Annual Cutest Pets on Parliament Hill awards celebration, where the winning pets of 2025 were officially crowned at a lively, pet-themed gala hosted by the …

Les animaux de compagnie les plus mignons sur la Colline du Parlement 2025 : Les gagnants sont dévoilés lors d’un gala où les vedettes portaient de riches fourrures

Les animaux de compagnie les plus mignons sur la Colline du Parlement 2025 : Les gagnants sont dévoilés lors d’un gala où les vedettes portaient de riches fourrures

OTTAWA, Ontario, 05 juin 2025 (GLOBE NEWSWIRE) -- La troisième cérémonie annuelle de remise des prix pour le concours « Les animaux de compagnie les plus mignons sur la Colline du Parlement » a été mémorable. Les gagnants de 2025 ont été officiellement …

Osivax Announces Last Patient Last Visit  in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed …

Merus N.V. annonce une offre publique de souscription d’actions ordinaires

Merus N.V. annonce une offre publique de souscription d’actions ordinaires

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants …

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the …

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié

Communiqué de presse : Sanofi lance son plan mondial 2025 d’actionnariat salarié

Sanofi lance son plan mondial 2025 d’actionnariat salarié Paris, le 5 juin 2025. Sanofi lance Action 2025, son plan mondial d’actionnariat salarié, qui sera ouvert le 10 juin 2025 à environ 70 000 salariés dans 55 pays. Ce plan, qui entre dans sa onzième …

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

Lehi, June 05, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 5, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform designed to use the body’s immune system to treat cancer, today announced the successful creation …

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s …

Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan

Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan

Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence’s AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B …

Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen weitere Meilensteinzahlung an Basilea aus

Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen weitere Meilensteinzahlung an Basilea aus

Allschwil, 05. Juni 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab …

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY …

Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions